Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > What's up?

<< Previous

Bullboard Posts

Next >>

Comment by gebremeskelon May 14, 2024 4:48pm

197 Views

Post# 36039680

RE:RE:RE:What's up?

We're halfway through May and in a month and a half we'll be halfway through 2024.

Baxter is committed to separating from their kidney care division in the second half of 2024 and the distribution deal with Spectral will likely be part of the sale or will be part of the spinoff. There is a possibility of a Spectral buyout.

If enrolment continues at the present rate the trial could be finished around the end of the year and as good results seem very likely we may see the beginning of commercialization of a new standard of care treatment for sepsis in 2025.

So I think now is the time to buy.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale